Bioavailability Enhancement Strategies for Targeted Protein Degraders

Targeted protein degraders (TPDs), including PROTACs and molecular glues, represent a transformative therapeutic approach but face significant challenges in oral delivery due to their size, polarity, and poor solubility. Enhancing bioavailability is therefore critical to unlocking their full clinical potential. In this presentation, David O’Connell, Director of Scientific Affairs at PCI Pharma Services, will explore the latest bioavailability enhancement strategies for TPDs, from hot melt extrusion and nanomilling to advanced spray drying and nanotechnology. He will also highlight PCI’s strategic partnerships with leading solubility experts, enabling integrated, end-to-end solutions that accelerate development and improve outcomes for complex molecules.